Nisa Investment Advisors
RNAC icon

Nisa Investment Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Nisa Investment Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-107
Closed -$1.09K – 3062
2025
Q3 		$1.09K Buy
107
+64
+149% +$719 ﹤0.01% 2723
2025
Q2 		$447 Sell
43
-1
-2% -$11 ﹤0.01% 2891
2025
Q1 		$580 Sell
44
-4
-8% -$71 ﹤0.01% 2767
2024
Q4 		$860 Buy
48
+37
+336% +$749 ﹤0.01% 2711
2024
Q3 		$177 Sell
11
-3
-21% -$47 ﹤0.01% 2868
2024
Q2 		$378 Buy
+14
New +$334 ﹤0.01% 2739

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nisa Investment Advisors's RNAC Position: Q4 2025 in Review

Nisa Investment Advisors sold out of Cartesian Therapeutics (RNAC) in Q4 2025, closing a stake of 107 shares — an estimated $1.09K sold.

Nisa Investment Advisors first reported a position in RNAC in Q2 2024 and held it in 6 quarters. The position peaked at $1.09K in Q3 2025. 67 funds tracked by Wall St. Rank hold RNAC as of Q4 2025.

  • Nisa Investment Advisors reported no remaining Cartesian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Nisa Investment Advisors sold 107 Cartesian Therapeutics shares in Q4 2025, an estimated $1.09K.
  • Nisa Investment Advisors first reported a position in Cartesian Therapeutics in Q2 2024 and held it in 6 quarters.
  • Nisa Investment Advisors's Cartesian Therapeutics position peaked at $1.09K in Q3 2025.
  • 67 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2025.

Based on Nisa Investment Advisors's 13F filing for Q4 2025, filed 15 Jan 2026.